Ocutrx Technologies Inc. Unveils Surgery Breakthrough: First-Ever Technology to Make Blood Translucent During Surgery

IRVINE, Calif. and ABU DHABI, UAE, June 24, 2025 /PRNewswire/ -- Ocutrx Technologies Inc. ("Ocutrx"), through its R&D division Genius Labs, today unveiled a major surgical innovation: the ability to render blood translucent in real time during surgery. This patent-pending advancement enables surgeons to see through pooled blood without the need for suction or irrigation—a world first. The technology, called HemoLucence™, will be a feature of the OR-Bot™ 3D Surgical Microscope System, which is scheduled to enter clinical trials in 2025 or 2026.

The HemoLucence technology is powered by Ocutrx’s proprietary algorithmic AI and digital engine, which is integrated into the OR-Bot™ system. The technology utilizes digital volumetric reconstruction and advanced de-scattering algorithms to visualize obscured anatomy under the blood. In tests, the system successfully visualized through three millimeters, approximately one-quarter inch, of whole human blood, which includes all major blood components. In further tests, the company expects to be able to visualize under at least half an inch of blood.

“The Ocutrx OR-Bot 3D Surgery Microscope’s ability to turn blood clear during surgery is a monumental achievement for the future of surgery, and a new high mark for Ocutrx’s journey towards pioneering innovation in healthcare,” said Michael A. H. Freeman, J.D., CEO/CTO of Ocutrx. “Our team at the Ocutrx Genius Labs worked tirelessly with me for two years to develop this remarkable technology that sets a new bar for surgical precision and visualization.”

Sign up for Blog Updates